SOURCE-LINKED STUDY SUMMARY
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized comparison of three tirzepatide doses with semaglutide 1 mg for blood sugar control.
- Who / model studied
- 1879 people with type 2 diabetes followed for 40 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary outcome, long-term blood sugar measured by glycated hemoglobin, fell 2.01, 2.24 and 2.30 percentage points across increasing tirzepatide doses, versus 1.86 with semaglutide. Weight loss was greater by 1.9, 3.6 and 5.5 kg, respectively. Digestive adverse events were common. Serious adverse events occurred in 5 to 7% versus 3%.
- Limitations & context
- The trial used an open-label design.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2107519